基于Mpro的针对性抗SARS-CoV-2抑制剂的药物
Zhuxin She1, Yinuo Yao1, Conglong Wang1
1College of Food Science and Light Industry, Nanjing Tech University, Nanjing, P.R. China.
Journal of chemical research
|July 17, 2023
概括
研究人员审查了针对主要蛋白酶 (Mpro) 的COVID-19药物. 这些抑制剂在治疗当前和未来的SARS-CoV-2变种方面表现有前途.
科学领域:
- 病毒学 病毒学
- 药物发现 药物发现 药物发现
- 药用化学 医学化学
背景情况:
- 严重急性呼吸系统综合征冠状病毒2 (SARS-CoV-2) 导致正在进行的COVID-19大流行.
- SARS-CoV-2 主蛋白酶 (Mpro) 对于病毒复制和验证的药物标至关重要.
- 维护Mpro的结构有助于开发广泛的抗病毒药物.
研究的目的:
- 综合审查自2019年底以来发现的SARS-CoV-2 Mpro抑制剂.
- 为开发针对SARS-CoV-2的新治疗策略提供参考.
- 为了帮助设计治疗新出现的SARS-CoV-2菌株与免疫逃避的治疗方法.
主要方法:
- 科学出版物和药物发现数据库的文献评论.
- 报告的SARS-CoV-2 Mpro抑制剂的分析.
- 在体外评估化合物对SARS-CoV-2 Mpro的疗效.
主要成果:
- 已经确定了许多针对SARS-CoV-2 Mpro的小分子抑制剂.
- 所有审查的化合物都在体外表现出对SARS-CoV-2 Mpro的抑制活性.
- 维护Mpro的保护性质支持开发有效的抗病毒药物.
结论:
- 审查的Mpro抑制剂为COVID-19药物开发提供了宝贵的资源.
- 针对Mpro仍然是一个可行的策略来打击SARS-CoV-2.
- 未来的研究应该集中在对新出现的SARS-CoV-2变种有效的抑制剂上.
更多相关视频
10:29Quantitative Structure-Activity Relationship, Activity Prediction, and Molecular Dynamics of Non-nucleotide Reverse Transcriptase Inhibitors
Published on: May 9, 2025
1.3K
10:21Author Spotlight: Streamlining Protein Target Prediction and Validation via Molecular Docking and CETSA
Published on: February 23, 2024
2.7K
相关概念视频
Targeted Cancer Therapies
7.7K
The targeted cancer therapies, also known as “molecular targeted therapies,” take advantage of the molecular and genetic differences between the cancer cells and the normal cells. It needs a thorough understanding of the cancer cells to develop drugs that can target specific molecular aspects that drive the growth, progression, and spread of cancer cells without affecting the growth and survival of other normal cells in the body.
There are several types of targeted therapies against...
There are several types of targeted therapies against...
7.7K
Targets for Drug Action: Overview
6.4K
Drugs target macromolecules to modify ongoing cellular processes. Primary drug targets include receptors, ion channels, transporters, and enzymes.
Receptors are either membrane-spanning or intracellular proteins, which upon binding a ligand, get activated and transmit the signal downstream to elicit a response. Drugs bind receptors, either mimicking the action of endogenous ligands or blocking the receptor activity to bring about a modified response. Nearly 35% of approved drugs target the G...
Receptors are either membrane-spanning or intracellular proteins, which upon binding a ligand, get activated and transmit the signal downstream to elicit a response. Drugs bind receptors, either mimicking the action of endogenous ligands or blocking the receptor activity to bring about a modified response. Nearly 35% of approved drugs target the G...
6.4K
Treatment for Pulmonary Arterial Hypertension: Prostacyclin Receptor Agonists
218
Prostacyclin receptor agonists are a class of therapeutic agents integral to managing pulmonary arterial hypertension (PAH). These drugs operate by mimicking the action of prostaglandin I2, or PGI2, a naturally occurring compound in the body.
These agonists bind to the IPR receptor situated on the plasma membrane of the pulmonary artery smooth muscle cells. This binding triggers a cascade of reactions known as the GS-AC-cAMP-PKA pathway. This pathway results in the relaxation of smooth muscle...
These agonists bind to the IPR receptor situated on the plasma membrane of the pulmonary artery smooth muscle cells. This binding triggers a cascade of reactions known as the GS-AC-cAMP-PKA pathway. This pathway results in the relaxation of smooth muscle...
218
Treatment for Pulmonary Arterial Hypertension: Endothelin Receptor Antagonists
202
Endothelins (ETs) are potent vasoactive peptides critical in the human body's various physiological and pathological processes. One of the most promising therapeutic strategies for treating pulmonary arterial hypertension (PAH) involves counteracting the effects of these endothelins using a class of drugs known as endothelin receptor antagonists.
ETs are synthesized through a complex sequence of enzymatic steps, primarily involving an enzyme referred to as endothelin-converting enzyme...
ETs are synthesized through a complex sequence of enzymatic steps, primarily involving an enzyme referred to as endothelin-converting enzyme...
202
